Suven Life presents Alzheimer's drug data in Austria meet
BS Reporter / Hyderabad Jul 27, 2009, 15:21 IST
Suven Life Sciences Limited, a Hyderabad-based biopharmaceutical company specialising in central nervous system (CNS) diseases, has presented the clinical Phase-I data for its SUVN-502 drug at the 2009 Alzheimer’s Association International Conference in Vienna, Austria.
The study was conducted at Basel, Switzerland, under a clinical trial application approved by SwissMedic, the regulatory authority of Switzerland for therapeutic products.
“The Phase-I clinical data has attracted a lot of scientific and commercial interest from global pharma companies. We believe that SUVN-502 has great potential to become a novel treatment for disorders affecting memory and cognition in Alzheimer’s, schizophrenia and other dementia,” Venkat Jasi, chief executive of Suven Life, said in a release on Monday.
The necessary additional tox studies are already in progress to start the Phase-II proof-of-concept study during 2010. The company targets to launch SUVN-502 in the latter part of 2013 or early 2014. Other molecules in the same category under development include GlaxoSmithKline’s molecule, which is at present in Phase-II, said Ramakrishna Nirogi, vice-president (discovery research), Suven Life.
Suven Life Sciences’ scrip is currently trading at Rs 22.10 on the BSE, up 6.76 per cent as against the previous close of Rs 20.70.
Any research that provides additional insight into Alzheimer's is critical to finding a cure. It's also important for patients and families affected by Alzheimer's to consider participating in clinical studies. Another current study is the ICARA Study, whose goal is to explore if an investigational drug, called Bapineuzumab, can help slow the progression of Alzheimer's Disease. Patients and families affected by Alzheimer's can visit www.icarastudy.com to see if they might be eligible to enroll.
Content Guide
